source
- BioNTech veteran secures $25M seed round for virtual cancer surveillance startupA new virtual cancer surveillance company has closed a $25 million seed round, with the funding led by investors attracted to its novel approach to monitoring tumors. The company is headed by Ryan…
- Silence spells out Phase 2 success for gene-silencing drug in rare blood cancerSilence Therapeutics is set to advance its siRNA drug for the rare blood disorder polycythemia vera (PV) into Phase 3 following a successful mid-stage trial. Silence said its drug divesiran met the…Endpoints · 1h ago↗ source